Wells Fargo initiated coverage on Thermo Fisher with a new price target
$TMO
Industrial Machinery/Components
Industrials
Wells Fargo initiated coverage of Thermo Fisher with a rating of Overweight and set a new price target of $670.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2025 | Outperform | William Blair | |
| 7/24/2025 | $510.00 | Buy → Hold | HSBC Securities |
| 7/11/2025 | $590.00 | Sector Perform → Sector Outperform | Scotiabank |
| 7/9/2025 | $460.00 | Buy → Neutral | UBS |
| 1/10/2025 | $630.00 | Mkt Perform → Outperform | Bernstein |
| 12/23/2024 | Sector Perform | Scotiabank | |
| 10/14/2024 | Buy | Redburn Atlantic | |
| 10/1/2024 | $680.00 | Overweight | Stephens |
10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr
Thermo Fisher to Acquire Sanofi's Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will ex
William Blair initiated coverage of Thermo Fisher with a rating of Outperform
HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00
Scotiabank upgraded Thermo Fisher from Sector Perform to Sector Outperform and set a new price target of $590.00
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)
Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition
908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov